Filtreler
The comparison in terms of early complications of a new technique and percutaneous method for the placement of CAPD catheters

Borazan A. | Comert M. | Ucan B.H. | Comert F.B. | Sert M. | Sekitmez N. | Cesur A.

Article | 2006 | Renal Failure28 ( 1 ) , pp.37 - 42

Background. Starting continuous ambulatory peritoneal dialysis (CAPD) immediately after insertion of a peritoneal dialysis catheter is essential in end-stage renal disease (ESRD). In relation to the insertion methods, various mechanical and infectious complications may arise. In this study, we aimed to compare early complications of the laparoscopic tunneling method of CAPD placement that we developed recently in order to minimize the complications, with those of the conventional percutaneous method. Subjects and method. Included in this study were 12 consecutive patients with ESRD to whom we introduced catheters for CAPD by way of . . .laparoscopic tunneling between April 2003 and July 2003 and followed up for at least 6 months, and 30 patients to whom the catheters were placed percutaneously in the same time period with the same follow-up time. The complications seen during the first 6 months after catheter placement with these two different methods were compared. Results. In all of the subjects, dialysis was started soon after catheter placement. No peroperative morbidity was seen in any of the patients. While with laparoscopic tunneling method no mechanical problem was seen, the percutaneous method resulted in early leakage in 10%, pericatheter bleeding in 3.3%, and hernia in 3.3% of the patients. As infectious complications, peritonitis occurred as one episode/36 patient-months in laparoscopic tunneling and one episode/22.5 patient-months in percutaneous method; catheter insertion site infection was seen in none in the laparoscopic method, while one episode/90patient-months was seen with the percutaneous method. Tunnel infection did not arise in any of the subjects. Conclusion. The authors of this study think that the peritoneal tunneling method for introducing CAPD, which has been recently developed and began to be routinely used by them, is rather safe in terms of early complications. Copyright © Taylor & Francis Group, LLC Daha fazlası Daha az

Assessment of tumor markers in patients with chronic renal failure

Engin H. | Borazan A. | Aydemir S. | Yilmaz A.

Article | 2007 | Turkish Journal of Cancer37 ( 4 ) , pp.143 - 147

In this study; serum levels of different tumor markers such as alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen 125 (CA 125), cancer antigen 19-9 (CA 19-9), cancer antigen 15-3 (CA 15-3), and prostatespecific antigen (PSA) in 36 predialysis, 42 hemodialysis (HD), 42 continuous ambulatory peritoneal dialysis (CAPD) patients and 32 healthy volunteers as control group who did not present any clinical symptoms or signs of neoplasia with negative hepatitis markers were studied. The mean serum levels of CEA and CA 19-9 were found to be higher than the control group in predialysis, HD and CAPD patients. Serum levels . . .of CA 125 in CAPD group was found to be higher as compared to the other groups. Serum AFP, CA 15-3 and PSA levels were similar in all groups. In conclusion, serum tumor markers do not have any diagnostic utility and may be unreliable for monitoring malignancies in uremic patients Daha fazlası Daha az

The effects of haemodialysis and peritoneal dialysis on serum lipoprotein(a) and C-reactive protein levels

Borazan A. | Üstün H. | Yilmaz A.

Article | 2003 | Journal of International Medical Research31 ( 5 ) , pp.378 - 383

Elevated serum lipoprotein(a) is an independent risk factor for coronary artery disease, and C-reactive protein (CRP) is a general and cardiovascular marker in haemodialysis patients. We studied lipoprotein(a) and CRP levels in 48 haemodialysis and 24 continuous ambulatory peritoneal dialysis (CAPD) patients and 20 healthy individuals, after a 12 h fast. Serum lipoprotein(a) levels were elevated in 31.3%, 66.7% and 5% of haemodialysis and CAPD patients and control subjects, respectively. The difference between all groups was significant. Serum CRP levels were high in 43.8%, 58.4% and 5% of haemodialysis and CAPD patients, and health . . .y subjects, respectively. The mean serum CRP level was significantly different between all groups. Both protein levels were higher in CAPD patients than haemodialysis patients, suggesting that CAPD patients should be more closely monitored for coronary artery disease Daha fazlası Daha az

The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels

Borazan A. | Aydemir S. | Sert M. | Yilmaz A.

Article | 2004 | Mediators of Inflammation13 ( 05.Jun ) , pp.361 - 364

OBJECTIVES: In this study, we aimed to investigate plasma homocystetoe (Hcy) and serum C-reactive protein (CRP) levels in hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) patients, and the relation among them. Materials and methods: This study was carried out on 52 HD patients, 26 CAPD patients and a control group of 22 healthy persons. Blood samples were taken from the patients for Hcy and CRP measurements. Results: Serum CRP level was found to be high in 48.1% of HD patients, 69.2% of CAPD patients and 4.5% of the healthy control group. Plasma Hcy level was found out to be above the normal limits in 73.1% of . . .HD patients, 65.4% of CAPD patients and 9% of the healthy control group. There was a significant positive relation (r = 0.384, p < 0.001) between the levels of plasma Hcy and serum CRP in HD and CAPD patients. Conclusion: The high levels of Hcy and CRP were found out to be higher in HD and CAPD patients than in the control group. In order to determine the risk rate of Hcy and CRP for coronary artery disease, extensive investigations are required in patients with chronic renal failure that also have coronary artery disease Daha fazlası Daha az

The effects of continuous ambulatory peritoneal dialysis and hemodialysis on serum pepsinogen concentrations in patients with chronic renal failure

Aydemir S. | Borazan A. | Acikgoz S. | Ustundag Y. | Yilmaz A.

Article | 2005 | Tohoku Journal of Experimental Medicine205 ( 3 ) , pp.263 - 268

Pepsinogen, the precursors of pepsin, is classified into two subtypes: pepsinogen I (PG I) and pepsinogen II (PG II). Patients with impaired renal function are associated with elevated concentrations of serum pepsinogen. Contradictory results have been reported about the effect of dialysis on the serum pepsinogen levels, as the previous studies were conducted only in a particular period of dialysis. We therefore investigated the effect of continuous ambulatory peritoneal dialysis (CAPD) or hemodialysis on serum pepsinogen levels in patients with chronic renal failure (CRF) before and after dialysis treatment. Thirty-four patients wi . . .th CRF were enrolled in this study and were treated by CAPD (n = 22) or hemodialysis (n = 12). As a control group, subjects with normal renal function were included (n = 20). Serum PG I and PG II levels were measured in control subjects and CRF patients before dialysis treatment and after three-month dialysis treatment. Before dialysis treatment, serum PG I levels were significantly higher in CRF patients than control subjects. In patients treated by CAPD, the serum PG I levels were significantly decreased but its levels were still higher than the values of the control subjects, whereas PG I levels remained unchanged in patients treated by hemodialysis. There were no differences in serum PG II levels between control subjects and CRF patients before or after dialysis treatment. Thus, CAPD is more effective than hemodialysis in the clearance of PG I. © 2005 Tohoku University Medical Press Daha fazlası Daha az

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms